Oncology and specialty pharma R&D with digital pathology and clinical trial infrastructure
Daiichi Sankyo US operates a large pharmaceutical R&D organization focused on oncology and specialty medicines, with 91 active roles across sales, healthcare, operations, and research. The tech stack signals a hybrid approach: Salesforce + SAP handle commercial and supply-chain operations, while Python + PyTorch + TensorFlow + scikit-learn point to active ML and data-science work—likely supporting drug discovery and pathology analysis. Active projects around digital pathology partnerships, CDX (companion diagnostics) strategy, and RMP (risk management plan) initiatives indicate investment in precision medicine and regulatory infrastructure rather than traditional drug manufacturing.
Notable leadership hires: Project Lead, Diagnostic Lead, Medical Affairs Director, Study Delivery Lead
Daiichi Sankyo US is the US subsidiary of a global pharmaceutical company developing oncology and specialty medicines for cancer, cardiovascular, and high-unmet-need diseases. The organization spans R&D, clinical operations, medical affairs, sales, and supply-chain management across the United States. Current operational focus includes clinical trial protocol development, companion diagnostics strategy, digital pathology capabilities (both internal and via partnerships), and risk management processes. Hiring is concentrated in sales and healthcare roles, with notable leadership gaps in project delivery, diagnostic, and medical affairs leadership.
Primary stack: Salesforce (CRM), SAP + SAP Fiori (ERP), Azure OpenAI + LangChain (AI/ML), Python + PyTorch + TensorFlow + scikit-learn (data science), Veeva Vault (regulated data), Tableau + Power BI (analytics), SAS (statistical analysis).
Current projects: digital pathology (internal capabilities and partnerships), companion diagnostics strategy, clinical trial protocols, risk management plans, vendor/CRO oversight, and CMC (chemistry, manufacturing, controls) data modernization.
Other companies in the same industry, closest in size